Spots Global Cancer Trial Database for pimasertib
Every month we try and update this database with for pimasertib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Oral Bioavailability and Mass Balance Trial With Pimasertib | NCT01713036 | Locally Advance... | Pimasertib | 18 Years - 65 Years | Merck KGaA, Darmstadt, Germany | |
| A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | NCT01668017 | Advanced Solid ... Hepatocellular ... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Relative Bioavailability of Pimasertib in Cancer Patients | NCT01992874 | Neoplasms | Pimasertib Caps... Pimasertib Tabl... Pimasertib Tabl... Pimasertib Caps... Pimasertib Caps... | 18 Years - 80 Years | EMD Serono | |
| Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | NCT01693068 | N-Ras Mutated L... | Pimasertib Dacarbazine | 18 Years - | EMD Serono | |
| Trial of Pimasertib in Hematological Malignancies | NCT00957580 | Leukemia, Myelo... Hematologic Neo... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | EMD Serono | |
| MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | NCT01085331 | Metastatic Colo... | Pimasertib Placebo FOLFIRI | 18 Years - | EMD Serono | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | NCT06208657 | Childhood Cance... Childhood Solid... Childhood Brain... Recurrent Cance... Refractory Canc... | Paxalisib, Irin... Pimasertib | 0 Years - 21 Years | Australian & New Zealand Children's Haematology/Oncology Group | |
| A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients | NCT01985191 | Neoplasm Malign... | SAR405838 Pimasertib | 18 Years - | Sanofi | |
| Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | NCT01016483 | Pancreatic Aden... | Pimasertib Gemcitabine Placebo | 18 Years - | EMD Serono | |
| Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus | NCT01378377 | Advanced Solid ... | Pimasertib Pimasertib Temsirolimus Temsirolimus | 18 Years - | EMD Serono | |
| Oral Bioavailability and Mass Balance Trial With Pimasertib | NCT01713036 | Locally Advance... | Pimasertib | 18 Years - 65 Years | Merck KGaA, Darmstadt, Germany | |
| Trial of Pimasertib in Hematological Malignancies | NCT00957580 | Leukemia, Myelo... Hematologic Neo... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | EMD Serono | |
| A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | NCT01668017 | Advanced Solid ... Hepatocellular ... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | Merck KGaA, Darmstadt, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
